4344-87-0

Usage

Uses

Used in Pharmaceutical Industry:
3-Methyl-3-pyrazolin-5-one is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with potential therapeutic properties.
Used in Chemical Synthesis:
3-Methyl-3-pyrazolin-5-one is used as a building block in the preparation of substituted 4-alkyl(cycloalkyl)-2-amino-3-cyano-4H-pyrans. These compounds have potential applications in various chemical processes and can be further modified to create new molecules with specific properties.

Upstream product

• 3075-23-8 S-ethyl acetothioacetate 
• 81675-28-7 1-amino-6-hydroxy-6-methyl-5,6-dihydrouracil 
• 112698-24-5 methyl-4 dihydro-3,7 pyrazolo<1,5,4-ef>benzodiazepine-1,5 one-6 
• 71653-63-9 Riodipine 
• 5396-89-4 benzyl acetoacetate 
• 64-19-7 acetic acid 
• 644-64-4 dimetilan 
• 141-97-9 ethyl acetoacetate 
• 302-01-2 hydrazine 
• 105-45-3 acetoacetic acid methyl ester 
• 161374-07-8 ethyl 4-(4-methoxyphenyl)-6-methyl-1,2,3,4-tetrahydropyrimidin-2-one-5-carboxylate 
• 5948-71-0 4-(4-chlorophenyl)-5-(ethoxycarbonyl)-6-methyl-3,4-dihydropyrimidin-2(1H)-one 
• 123043-88-9 5-ethoxycarbonyl-4-phenyl-6-methyl-3,4-dihydropyrimidine-2(1H)-thione 
• 185023-34-1 5-carboethoxy-6-methyl-4-(4-methylphenyl)-1H-pyrimidin-2-thione 

Downstream Products

• 4344-72-3 4,5-dimethyl-1,2-dihydro-pyrazol-3-one 
• 107-92-6 butyric acid 
• 7626-82-6 2-benzyl-5-methyl-1,2-dihydro-pyrazol-3-one 
• 5203-93-0 1-benzoyl-5-benzoyloxy-3-methyl-1H-pyrazole 
• 141762-99-4 2-ethyl-5-methyl-1,2-dihydro-pyrazol-3-one 
• 61885-21-0 1,2-dihydro-5-methyl-4-nitropyrazol-3-one 
• 2532-43-6 dimethyl-carbamic acid-(5-methyl-1(2)H-pyrazol-3-yl ester) 
• 89363-91-7 4-bromo-5-methyl-1,2-dihydro-3H-pyrazol-3-one 
• 33549-66-5 4,4-dibromo-5-methyl-2,4-dihydro-3H-pyrazol-3-one 
• 108-35-0 thiophosphoric acid O,O'-diethyl ester-O''-(5-methyl-1(2)H-pyrazol-3-yl ester) 
• 23326-27-4 Methyl 2-butynoate 

Relevant academic research and scientific papers

“On-water” one-pot four-component synthesis of novel 1H-furo[2,3-c]pyrazole-4-amine derivatives

A catalyst-free, simple and green protocol has been accomplished for the synthesis of novel 1H-furo[2,3-c]pyrazole-4-amines in a one-pot four-component domino reaction involving hydrazines, ethyl acetoacetate, aromatic amines and phenylglyoxal monohydrate in water. The protocol presented herein describes in situ generated pyrazolone as intermediate reactants with phenylglyoxal monohydrate in a Knoevenagel condensation followed by a Michael addition of amine, intramolecular cyclization, dehydration and the resulting to the title compound. It was observed that in this protocol bis(pyrazole-5-ols) are formed with amines bearing strong electron withdrawing groups under similar reaction conditions instead of the expected products. The reaction merits the use of water as solvent, no additive catalyst, easy workup, easy purification of products by non-chromatography and provides high yield of products with good purity.

Reaction of 3,5-carbonyl-substituted 1,4-dihydropyridines with hydrazine hydrate

The interaction of 3,5-carbonyl-substituted derivatives of 1,4-dihydropyridine and some analogs of it with hydrazine hydrate occurs with fission of the heterocycle. In the case of alkoxycarbonyl-substituted compounds a reverse Michael reaction predominate

Meglumine catalyzed one pot synthesis of new fluorescent 2-amino-4-pyrazolyl-6-aryldiazenyl-4H-chromene-3-carbonitriles

Meglumine, a biodegradable basic organo-catalyst has been efficiently explored for the one-pot synthesis of new fluorescent 2-amino-4-(5-hydroxy-3-methyl-1H-pyrazol-4-yl)-6-aryldiazenyl-4H-chromene-3-carbonitriles in an aqueous medium at room temperature. The synthesized compounds were found highly fluorescent when screened for photoluminescence properties. The planar structure equipped with substituted aryldiazenyl group led to the extension of conjugation that facilitated fluorescence emission in the visible region with a large stokes shift of 290–294 nm. The novelty of work is a synthesis of highly conjugated molecular assembly, high yield in shorter reaction time, energy efficiency, atom economy, utilization of water as a universal green solvent and meglumine as an eco-benign organo-catalyst.

Synthesis of 1,3,5-Trisubstituted Pyrazoles and Hydrazones Using Fe3O4?CeO2 Nanocomposite as an Efficient Heterogeneous Nanocatalyst

Abstract: Pyrazoles and hydrazones, as two significant kinds of potentially bioactivecompounds, were produced with good to excellent yields by condensation ofβ-dicarbonyl compounds with hydrazines in aqueous media in the presence ofFe3O4?CeO2nanocomposite as an efficient heterogeneous nanocatalyst. The magneticnanocatalyst can readily be separated using an external magnet and reused atleast six times without significant loss in activity. The products werecharacterized by IR and 1H and13C NMR spectra.

Solvent-free ring cleavage hydrazinolysis of certain biginelli pyrimidines

Certain Biginelli pyrimidines with ester substitution in C5 were subjected to unexpected ring opening upon solvent-free reaction with hydrazine hydrate to give three products: pyrazole, arylidenehydrazines, and urea/thiourea, respectively. The nonisolable carbohydrazide intermediates are formed firstly followed by the intermolecular nucleophilic attack of terminal amino group of hydrazide function on sp2 C6 rather than the sp3 C4 to give the ring adduct which was produced as a final product.

Focal adhesion kinase inhibitor and use

The invention belongs to the field of medicines, relates to a focal adhesion kinase inhibitor and use, in particular relates to a novel focal adhesion kinase inhibitor compound, or stereoisomers, geometric isomers, tautomers, oxynitrides, hydrates, solvates, metabolites, pharmaceutically acceptable salts or prodrugs thereof, further relates to the use of the compound and pharmaceutical compositions as medicines, in particular the use of the compound and pharmaceutical compositions in manufacture of medicines for treatment or prevention of cancer, pulmonary hypertension, and pathological angiogenesis-related diseases.

Method for preparing pyridinyl-pyrazole compound

The invention discloses a method for preparing a pyridinyl-pyrazole compound of 1-(2-aminopyridine-4-yl)-3-methyl-1H-pyrazole-5-ol. Ethyl acetoacetate is adopted a starting raw material, and the target product is obtained through cyclization, condensation and reduction. The compound is an important pharmaceutical intermediate.

Preparation method of pyrazole compound

The invention discloses a preparation method of a pyrazole compound, namely 1-(3-amino-5-(trifluoromethyl)phenyl)-3-methyl-1H-pyrazol-5-ol. The preparation method takes ethyl acetoacetate as a starting raw material and a target product is obtained through ring closure, condensation and reduction; the compound is an important pharmaceutical intermediate.

Preparation method of pyrazole compound

The invention discloses a preparation method of a pyrazole compound, namely 1-(3-nitrophenyl)-3-methyl-1H-pyrazole-5-chloride. The preparation method comprises the following steps: with ethyl acetoacetate as an initial raw material, performing ring closing, condensation and chlorination to obtain the target product. The compound is an important medical intermediate.

Preparation method of benzene substituted pyrazole derivative

The invention discloses a preparation method of a benzene substituted pyrazole derivative of 1-(3-trifluoromethylphenyl)-3-methyl-1H-pyrazole-5-chlorine. The preparation method comprises the following steps: by using ethyl acetoacetate as an initiating raw material, closing a loop, condensing, and chlorinating, so as to obtain a target product. The compound is an important medical intermediate.